Veritable’s SAB Biotherapeutics SABS Stock Holding History

Veritable’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50,651	Closed	-$420K	–	647
2023 Q2	$420K	Hold	50,651	–	–	0.01%	591
2023 Q1	$223K	Hold	50,651	–	–	﹤0.01%	795
2022 Q4	$299K	Buy	50,651 +46,296	+1,063%	+$423K	0.01%	661
2022 Q3	$31K	Hold	4,355	–	–	﹤0.01%	786
2022 Q2	$63K	Hold	4,355	–	–	﹤0.01%	869
2022 Q1	$164K	Hold	4,355	–	–	﹤0.01%	874
2021 Q4	$340K	Buy	+4,355	New	+$409K	0.01%	683

Other funds holding SABS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

PFO

Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

IFAM

Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Veritable's SABS Position: Q3 2023 in Review

Veritable sold out of SAB Biotherapeutics (SABS) in Q3 2023, closing a stake of 50,651 shares — an estimated $420K sold.

Veritable first reported a position in SABS in Q4 2021 and held it in 7 quarters. The position peaked at $420K in Q2 2023. 34 funds tracked by Wall St. Rank hold SABS as of Q3 2023.

Veritable reported no remaining SAB Biotherapeutics position as of Q3 2023 after selling out during the quarter.
Veritable sold 50,651 SAB Biotherapeutics shares in Q3 2023, an estimated $420K.
Veritable first reported a position in SAB Biotherapeutics in Q4 2021 and held it in 7 quarters.
Veritable's SAB Biotherapeutics position peaked at $420K in Q2 2023.
34 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2023.

Based on Veritable's 13F filing for Q3 2023.